Clinical implications of genomics for cancer risk genetics

The Lancet Oncology

Volumn 16, Issue 6, 2015, Pages e303-e308

  Thomas, David M ^a,b,c   James, Paul A ^b,c   Ballinger, Mandy L ^b,c  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CANCER RESEARCH; CANCER RISK; CLINICAL PRACTICE; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; HERITABILITY; HUMAN; NOTE; PRIORITY JOURNAL; TUMOR GENE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PATHOLOGY; RISK FACTOR;

GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 84930242380     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)70026-4     Document Type: Note

References (55)

1. Warthin AS Heredity with reference to carcinoma: as shown by the study of the cases examined in the pathological laboratory of the University of Michigan, 1895-1913. Arch Intern Med 1913, 12:546-555.
2. Broca P Traité des tumeurs 1866, P. Asselin, Paris.
3. Fearon ER, Vogelstein B A genetic model for colorectal tumorigenesis. Cell 1990, 61:759-767.
4. Gardner EJ A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum. Am J Hum Genet 1951, 3:167-176.
5. Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991, 66:589-600.
6. Joslyn G, Carlson M, Thliveris A, et al. Identification of deletion mutations and three new genes at the familial polyposis locus. Cell 1991, 66:601-613.
7. Hanahan D, Weinberg RA The hallmarks of cancer. Cell 2000, 100:57-70.
8. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
9. Forrest LE, Burke J, Bacic S, Amor DJ Increased genetic counseling support improves communication of genetic information in families. Genet Med 2008, 10:167-172.
10. MacArthur DG, Manolio TA, Dimmock DP, et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014, 508:469-476.
11. DNA sequencing costs National Human Genome Research Institute, (accessed April 7, 2015). http://www.genome.gov/sequencingcosts.
12. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
13. Bodmer W, Tomlinson I Rare genetic variants and the risk of cancer. Curr Opin Genet Dev 2010, 20:262-267.
14. Easton DF How many more breast cancer predisposition genes are there? Breast. Cancer Res 1999, 1:14-17.
15. Hemminki K, Li X, Sundquist K, Sundquist J Familial risks for common diseases: etiologic clues and guidance to gene identification. Mutat Res 2008, 658:247-258.
16. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med 2014, 371:497-506.
17. Le Calvez-Kelm F, Lesueur F, Damiola F, et al. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study. Breast Cancer Res 2011, 13:R6. the Breast Cancer Family Registry.
18. Tavtigian SV, Oefner PJ, Babikyan D, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet 2009, 85:427-446. the Australian Cancer Study, the Breast Cancer Family Registries (BCFR)the Breast Cancer Family Registries (BCFR), the Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab)the Kathleen Cuningham Foundation Consortium for Research into Familial Aspects of Breast Cancer (kConFab).
19. Bahcall O Common variation and heritability estimates for breast, ovarian and prostate cancers (accessed April 8, 2015). http://www.nature.com/icogs/primer/common-variation-and-heritability-estimates-for-breast-ovarian-and-prostate-cancers/.
20. Michailidou K, Hall P, Gonzalez-Neira A, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Gen 2013, 45:353-361.
21. Eeles RA, Olama AA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013, 45:385-391.
22. Pharoah PD, Tsai YY, Ramus SJ, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 2013, 45:362-370.
23. Cancer in Australia: in brief 2012 2012, Australian Institute of Health and Welfare, Australian Institute of Health and Welfare and Australasian Association of Cancer Registries, Canberra, Australia.
24. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011, 108:18032-18037.
25. Sawyer S, Mitchell G, McKinley J, et al. A role for common genomic variants in the assessment of familial breast cancer. J Clin Oncol 2012, 30:4330-4336.
26. Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612. American Thyroid Association Guidelines Task Force.
27. Spurdle AB, Whiley PJ, Thompson B, et al. BRCA1 R1699Q variant displaying ambiguous functional abrogation confers intermediate breast and ovarian cancer risk. J Med Genet 2012, 49:525-532.
28. Figueiredo BC, Sandrini R, Zambetti GP, et al. Penetrance of adrenocortical tumours associated with the germline TP53 R337H mutation. J Med Genet 2006, 43:91-96.
29. Ribeiro RC, Rodriguez-Galindo C, Figueiredo BC, et al. Germline TP53 R337H mutation is not sufficient to establish Li-Fraumeni or Li-Fraumeni-like syndrome. Cancer Lett 2007, 247:353-355.
30. Richards CS, Bale S, Bellissimo DB, et al. ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007. Genet Med 2008, 10:294-300.
31. Plon SE, Eccles DM, Easton D, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat 2008, 29:1282-1291. the IARC Unclassified Genetic Variants Working Group.
32. Custódio G, Parise GA, Kiesel Filho N, et al. Impact of neonatal screening and surveillance for the TP53 R337H mutation on early detection of childhood adrenocortical tumors. J Clin Oncol 2013, 31:2619-2626.
33. Villani A, Tabori U, Schiffman J, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncol 2011, 12:559-567.
34. Grant RC, Selander I, Connor AA, et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology 2015, 148:556-564.
35. Goodwin PJ, Phillips KA, West DW, et al. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study. J Clin Oncol 2012, 30:19-26.
36. Mitchell G, Ballinger ML, Wong S, et al. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One 2013, 8:e69026. the International Sarcoma Kindred Study.
37. Zhang L, Fleischut MH, Kohut K, et al. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. Clin Genet 2011, 80:97-98.
38. Kuipers EJ, Rosch T, Bretthauer M Colorectal cancer screening-optimising current strategies and new directions. Nat Rev Clin Oncol 2013, 10:130-142.
39. Tabar L, Yen MF, Vitak B, Chen HH, Smith RA, Duffy SW Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet 2003, 361:1405-1410.
40. The benefits and harms of breast cancer screening: an independent review. Lancet 2012, 380:1778-1786. Independent UK Panel on Breast Cancer Screening.
41. McBride KA, Ballinger ML, Killick E, et al. Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nat Rev Clin Oncol 2014, 11:260-271.
42. Wilhelm T, Stieltjes B, Schlemmer HP Whole-body-MR-diffusion weighted imaging in oncology. Rofo 2013, 185:950-958.
43. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999, 340:77-84.
44. Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011, 378:2081-2087.
45. Goss PE, Ingle JN, Alés-Martínez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011, 364:2381-2391.
46. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 2014, 383:1041-1048. the IBIS-II investigators.
47. Critchley J, Capewell S Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2003, 4. CD003041.
48. Mackay-Lyons M, Thornton M, Ruggles T, Che M Non-pharmacological interventions for preventing secondary vascular events after stroke or transient ischemic attack. Cochrane Database Syst Rev 2013, 3. CD008656.
49. Rothwell PM, Algra A, Amarenco P Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke. Lancet 2011, 377:1681-1692.
50. Pharoah PD, Antoniou AC, Easton DF, Ponder BA Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008, 358:2796-2803.
51. Hall AE, Chowdhury S, Hallowell N, et al. Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues. J Public Health (Oxf) 2014, 36:285-291.
52. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 2013, 15:565-574.
53. Foster C, Evans DG, Eeles R, et al. Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genet Test 2004, 8:23-29.
54. Brooks L, Lennard F, Shenton A, et al. BRCA1/2 predictive testing: a study of uptake in two centres. Eur J Hum Genet 2004, 12:654-662.
55. Craufurd D, Dodge A, Kerzin-Storrar L, Harris R Uptake of presymptomatic predictive testing for Huntington's disease. Lancet 1989, 2:603-605.